Skip to main content
OpenTrials

Clinical trial condition

Recurrent Bladder Carcinoma

Explore clinical trials studying Recurrent Bladder Carcinoma. Study availability and eligibility vary by location and protocol.

12 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Bladder Carcinoma trial results

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Thomas Hospital Fairhope, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
View all 1410 locations
View Trial Details
Active, not recruiting

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

NCT03047213

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +18 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 20 locations
View Trial Details
Completed

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

NCT01638533

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +125 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View Trial Details
Completed

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

NCT00118040

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +12 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • South Orange County Surgical Medical Group Inc Laguna Hills, California, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • AccuMed Research Associates Garden City, New York, United States
View Trial Details

Related conditions